New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
15:51 EDTPDIIHeartland Advisors raises stake in PDI, Inc. to 19.3% from 18.8%
Heartland has engaged, and may engage in the future, in communications with one or more officers of the company and/or one or more members of the board of directors of the company and/or one or more representatives of the company regarding the company, including but not limited to, its operations and ways in which the company can improve corporate governance and maximize stockholder value. Heartland may discuss ideas that, if effected, may result in changes in the board of directors or management of the company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use